Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers

Matthew E Growdon; Chana A Sacks; Aaron S Kesselheim; Jerry Avorn

doi:10.1001/jamainternmed.2019.3107

Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers

JAMA Intern Med. 2019 Aug 5;179(12):1712-1714. doi: 10.1001/jamainternmed.2019.3107. Online ahead of print.

Authors

Matthew E Growdon^{1

2}, Chana A Sacks^{1

3}, Aaron S Kesselheim¹, Jerry Avorn¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Harvard Medical School Multi-Campus Geriatric Fellowship, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston.

Abstract

This economic evaluation study estimates the potential Medicare savings from generic substitution and therapeutic interchange of brand-name hypertension medications.